Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

13G Filing: Eagle Asset Management Inc Updates Akebia Therapeutics, Inc. (AKBA) Position

A new 13G filing has been submitted to the SEC by Eagle Asset Management, in relation to the investor’s position in Akebia Therapeutics, Inc. (NASDAQ:AKBA), which stands at 12.91% of its common stock. The filing reveals the latest share ownership information of all relevant parties and subsidiaries of the investor, which you can see embedded in the table below. These 13G filings can prove invaluable to investors, as they show the latest moves made by top investors in stocks which they are or were very bullish on, and in a timely fashion in most cases. You can find the latest such filing embedded below and on the following pages.

You can access the original SEC filing by clicking here.

Page 1 of 1 SEC Filing

January 25, 2016

Securities and Exchange Commission
100 F Street NE
Washington, DC 20549

RE: Schedule 13G
Akebia Therapeutics Inc.
As of December 31, 2015

Gentlemen:

In accordance with Section 13(d)(5) of the Securities Exchange Act
of 1934, attached please find a copy of Schedule 13G for the above
named company showing a change in beneficial ownership of 10% or more
as of December 31, 2015 filed on behalf of Eagle Asset Management, Inc.

Very truly yours,

Damian Sousa
Vice President
Chief Compliance Officer
Enclosures

cc: Office of the Corporate Secretary
Akebia Therapeutics
245 First Street
Suite 1100
Cambridge, MA 02142

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Schedule 13G

Under the Securities Exchange Act of 1934
(Amendment No. 2 )*

Akebia Therapeutics, Inc
(Name of Issuer)

Common Stock
(Title of Class of Securities)

00972D105
(CUSIP Number)

Check the following box if a fee is being paid with this statement
_____. (A fee is not required only if the filing person: (1) has
a previous statement on file reporting beneficial ownership of more
than five percent of the class of securities described in Item 1;
and (2) has filed no amendment subsequent thereto reporting beneficial
ownership of five percent or less of such class.) (See Rule 13d-7.)

*The remainder of this cover page shall be filled out for a reporting
person’s initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information
which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not
be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of
the Act (however, see the Notes).

Page 1 of 5 Pages

CUSIP NO. 00972D105 13G

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Eagle Asset Management, Inc. 59-2385219

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (A) ______
(B) ______

3 SEC USE ONLY

4 CITIZENSHIP OR PLACE OF ORGANIZATION

State of Florida

NUMBER OF 5 SOLE VOTING POWER
SHARES 3,953,107
BENEFICIALLY 6 SHARED VOTING POWER
OWNED – – –
AS OF
Dec. 31, 2015 7 SOLE DISPOSITIVE POWER
BY EACH 3,953,107
REPORTING 8 SHARED DISPOSITIVE POWER
PERSON WITH – – –

9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

3,953,107

10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[_____]

11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

12.91%

12 TYPE OF REPORTING PERSON*

IA
_____________________________________________________________
*SEE INSTRUCTION BEFORE FILLING OUT!
_____________________________________________________________

Page 2 of 5 Pages
Item 1(a) Name of Issuer:

Akebia Therapeutics, Inc.

Item 1(b) Address of Issuer’s Principal Executing Offices:

245 First Street
Suite 1100
Cambridge, MA 98121

Item 2(a) Name of Person Filing:

Eagle Asset Management, Inc.

Item 2(b) Address of Principal Business Office:

880 Carillon Parkway
St. Petersburg, Florida 33716

Item 2(c) Citizenship:

Florida

Item 2(d) Title of Class of Securities:

Common Stock

Item 2(e) CUSIP Number:

00972D105

Item 3 Type of Reporting Person:

(e) Investment Adviser registered under Section 203 of the
Investment Advisors Act of 1940

Page 3 of 5 Pages
Item 4 Ownership as of Dec. 31, 2015

(a) Amount Beneficially Owned:

3,953,107 shares of common stock beneficially owned including:

No. of Shares
Eagle Asset Management, Inc. 3,953,107

(b) Percent of Class: 12.91%

(c) Deemed Voting Power and Disposition Power:

(i) (ii) (iii) (iv)
Deemed Deemed
Deemed Deemed to have to have
to have to have Sole Power Shared Power
Sole Power Shared Power to Dispose to Dispose
to Vote or to Vote or or to or to
to Direct to Direct Direct the Direct the
to Vote to Vote Disposition Disposition

Eagle Asset 3,953,107 —- 3,953,107 —-
Management, Inc.

Item 5 Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that
as of the date hereof the reporting person has ceased to be the beneficial owner
of more than five percent of the class of securities, check the following.
(____)

Item 6 Ownership of More than Five Percent on Behalf of Another Person:

N/A

Item 7 Identification and Classification of the Subsidiary which
Acquired the Security Being Reported on by the Parent Holding Company:

N/A

Page 4 of 5 Pages
Item 8 Identification and Classification of Members of the Group:
N/A

Item 9 Notice of Dissolution of Group:

N/A

Item 10 Certification:

By signing below I certify that to the best of my knowledge
and belief, the securities referred to above were acquired in
the ordinary course of business and were not acquired for purpose
of and do not have the effect of changing or influencing the control
of the issuer of such securities and were not acquired in connection
with or as a participant in any transaction having such purposes or effect.

Signature

After reasonable inquiry and to the best of my knowledge
and belief, I certify that the information set forth in this
statement is true, complete and correct.

Date: January 25, 2016 EAGLE ASSET MANAGEMENT, INC.

/s/ Damian Sousa
_________________________________
Damian Sousa
Vice President
Chief Compliance Officer

Page 5 of 5 Pages

Follow Akebia Therapeutics Inc. (NASDAQ:AKBA)
Trade (NASDAQ:AKBA) Now!